

# Bassel F El-Rayes

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/3670026/bassel-f-el-rayes-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

330 papers	8,134 citations	49 h-index	79 g-index
379 ext. papers	10,001 ext. citations	4.3 avg, IF	6.03 L-index

#	Paper	IF	Citations
330	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 801-810	21.7	494
329	Broad targeting of angiogenesis for cancer prevention and therapy. <i>Seminars in Cancer Biology</i> , <b>2015</b> , 35 Suppl, S224-S243	12.7	314
328	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, e204564	13.4	274
327	Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1357-70	2.2	213
326	Designing a broad-spectrum integrative approach for cancer prevention and treatment. <i>Seminars in Cancer Biology</i> , <b>2015</b> , 35 Suppl, S276-S304	12.7	179
325	Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 165-171	8.7	174
324	Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. <i>Pancreas</i> , <b>2013</b> , 42, 1311-5	2.6	153
323	Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4012-4012	2.2	136
322	Targeting the epidermal growth factor receptor. <i>British Journal of Cancer</i> , <b>2004</b> , 91, 418-24	8.7	126
321	Potential of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB. <i>Cancer Research</i> , <b>2006</b> , 66, 10553-9	10.1	116
320	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , <b>2019</b> , 111, 782-794	9.7	113
319	Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. <i>CardioVascular and Interventional Radiology</i> , <b>2013</b> , 36, 440-8	2.7	109
318	First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1112-8	2.2	105
317	Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. <i>Pancreas</i> , <b>2004</b> , 28, e90-5	2.6	102
316	Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. <i>Urology</i> , <b>2003</b> , 61, 774-80	1.6	98
315	Exploitation of protein kinase C: a useful target for cancer therapy. <i>Cancer Treatment Reviews</i> , <b>2009</b> , 35, 1-8	14.4	94
314	Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 809-818	8.7	92

313	Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis. <i>Carcinogenesis</i> , <b>2014</b> , 35, 967-73	4.6	88
312	mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). <i>Annals of Oncology</i> , <b>2013</b> , 24, 965-73	10.3	85
311	Pancreatic Ductal Adenocarcinoma is Spread to the Peripancreatic Soft Tissue in the Majority of Resected Cases, Rendering the AJCC T-Stage Protocol (7th Edition) Inapplicable and Insignificant: A Size-Based Staging System[(pT1: 0, pT2: >2-0, pT3: >4 cm) is More Valid and Clinically Relevant. <i>Annals of Surgical Oncology</i> , <b>2016</b> , 23, 2010-8	3.1	82
310	Hypoxia inducible factor-1[Its role in colorectal carcinogenesis and metastasis. <i>Cancer Letters</i> , <b>2015</b> , 366, 11-8	9.9	80
309	Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. <i>Cancer</i> , <b>2013</b> , 119, 285-92	6.4	80
308	A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1999-2004	10.3	80
307	A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. <i>Investigational New Drugs</i> , <b>2005</b> , 23, 583-90	4.3	80
306	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. <i>Molecular Therapy</i> , <b>2016</b> , 24, 1150-1158	11.7	79
305	Apoptosis-inducing effect of erlotinib is potentiated by 3,3[diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , <b>2008</b> , 7, 1708-19	6.1	75
304	Pronecrotic mixed lineage kinase domain-like protein expression is a prognostic biomarker in patients with early-stage resected pancreatic adenocarcinoma. <i>Cancer</i> , <b>2013</b> , 119, 3148-55	6.4	73
303	Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3727-32	2.2	71
302	The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. <i>Cancer</i> , <b>2019</b> , 125, 127-134	6.4	71
301	Identifying and targeting cancer stem cells in the treatment of gastric cancer. <i>Cancer</i> , <b>2017</b> , 123, 1303-1312	3.1	70
300	Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , <b>2014</b> , 25, 254-65	2.4	69
299	Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. <i>Annals of Surgery</i> , <b>2014</b> , 260, 494-501; discussion 501-3	7.8	69
298	Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. <i>Cancer Letters</i> , <b>2013</b> , 341, 195-203	9.9	68
297	Appendiceal Mucinous Neoplasms: Diagnosis and Management. <i>Oncologist</i> , <b>2017</b> , 22, 1107-1116	5.7	66
296	Substaging of Lymph Node Status in Resected Pancreatic Ductal Adenocarcinoma Has Strong Prognostic Correlations: Proposal for a Revised N Classification for TNM Staging. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22 Suppl 3, S1187-95	3.1	66

295	Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 327-327	2.2	64
294	The Potential of CAR T Cell Therapy in Pancreatic Cancer. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2166	8.4	63
293	Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 2295-301	3.1	61
292	The impact of curcumin on breast cancer. <i>Integrative Biology (United Kingdom)</i> , <b>2012</b> , 4, 996-1007	3.7	61
291	Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. <i>Cancer</i> , <b>2017</b> , 123, 345-356	6.4	60
290	Antiangiogenic effects of a novel synthetic curcumin analogue in pancreatic cancer. <i>Cancer Letters</i> , <b>2015</b> , 357, 557-65	9.9	59
289	Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer. <i>Molecular Carcinogenesis</i> , <b>2015</b> , 54, 1147-58	5	59
288	A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 1592-1599	8.7	59
287	Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1 $\alpha$ and STAT-3. <i>Angiogenesis</i> , <b>2013</b> , 16, 903-17	10.6	58
286	Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. <i>Molecular Cancer Therapeutics</i> , <b>2005</b> , 4, 1943-51	6.1	58
285	Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma. <i>Journal of Gastrointestinal Cancer</i> , <b>2013</b> , 44, 143-51	1.6	57
284	Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , <b>2013</b> , 24, 307-14	1.4	57
283	Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. <i>Journal of Surgical Oncology</i> , <b>2015</b> , 111, 1028-34	2.8	55
282	Pleiotropic effects of genistein in metabolic, inflammatory, and malignant diseases. <i>Nutrition Reviews</i> , <b>2013</b> , 71, 562-72	6.4	55
281	Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 718-726	2.2	49
280	Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles. <i>Molecular Cancer</i> , <b>2018</b> , 17, 177	42.1	48
279	In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 86, 469-76	4	47
278	Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy. <i>BMC Cancer</i> , <b>2019</b> , 19, 857	4.8	46

277	Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 2920-5	2.2	46
276	Combination of tolafenamic acid and curcumin induces colon cancer cell growth inhibition through modulating specific transcription factors and reactive oxygen species. <i>Oncotarget</i> , <b>2016</b> , 7, 3186-200	3.3	46
275	A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2016</b> , 96, 296-303	4	46
274	Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies. <i>Journal of Molecular Diagnostics</i> , <b>2016</b> , 18, 299-315	5.1	45
273	Inhibition of NF- $\kappa$ B translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer. <i>Cancer Letters</i> , <b>2016</b> , 373, 227-33	9.9	44
272	Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. <i>Cancer</i> , <b>2015</b> , 121, 2164-74	6.4	44
271	Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. <i>American Journal of Roentgenology</i> , <b>2014</b> , 203, W706-14	5.4	43
270	HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy. <i>Oncotarget</i> , <b>2014</b> , 5, 9980-91	3.3	43
269	A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. <i>Investigational New Drugs</i> , <b>2011</b> , 29, 694-9	4.3	42
268	Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. <i>Oncologist</i> , <b>2019</b> , 24, 1453-1461	5.7	42
267	Adenocarcinoma ex-goblet cell carcinoid (appendiceal-type crypt cell adenocarcinoma) is a morphologically distinct entity with highly aggressive behavior and frequent association with peritoneal/intra-abdominal dissemination: an analysis of 77 cases. <i>Modern Pathology</i> , <b>2016</b> , 29, 1243-53	9.8	41
266	A phase II study of carboplatin and paclitaxel in esophageal cancer. <i>Annals of Oncology</i> , <b>2004</b> , 15, 960-5	10.3	39
265	A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3541-3541	2.2	39
264	Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. <i>Oncologist</i> , <b>2016</b> , 21, 178-87	5.7	38
263	Aquaporins: Their role in gastrointestinal malignancies. <i>Cancer Letters</i> , <b>2016</b> , 373, 12-18	9.9	37
262	Ampullary carcinoma is often of mixed or hybrid histologic type: an analysis of reproducibility and clinical relevance of classification as pancreatobiliary versus intestinal in 232 cases. <i>Modern Pathology</i> , <b>2016</b> , 29, 1575-1585	9.8	35
261	Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 2699-705	3.1	35
260	Markers of resistance to anti-EGFR therapy in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , <b>2013</b> , 4, 308-18	2.8	35

259	Small molecule tolafenamic acid and dietary spice curcumin treatment enhances antiproliferative effect in pancreatic cancer cells via suppressing Sp1, disrupting NF- $\kappa$ B translocation to nucleus and cell cycle phase distribution. <i>Journal of Nutritional Biochemistry</i> , <b>2016</b> , 31, 77-87	6.3	33
258	An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment. <i>Cancer</i> , <b>2013</b> , 119, 445-53	6.4	33
257	Geographic differences in approach to advanced gastric cancer: Is there a standard approach?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2013</b> , 88, 416-26	7	33
256	Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib. <i>European Journal of Cancer</i> , <b>2016</b> , 52, 109-19	7.5	31
255	Imaging and curcumin delivery in pancreatic cancer cell lines using PEGylated $\text{EGd}_2(\text{MoO}_4)_3$ mesoporous particles. <i>Dalton Transactions</i> , <b>2014</b> , 43, 3330-8	4.3	30
254	CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer. <i>Cancer Research</i> , <b>2014</b> , 74, 2677-87	10.1	30
253	CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2010</b> , 6, 98-105	1.9	30
252	Incidence and Survival of Appendiceal Mucinous Neoplasms: A SEER Analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2017</b> , 40, 569-573	2.7	29
251	Novel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancer. <i>Molecular Carcinogenesis</i> , <b>2017</b> , 56, 288-299	5	29
250	Developments in the systemic therapy of pancreatic cancer. <i>Cancer Investigation</i> , <b>2003</b> , 21, 73-86	2.1	29
249	Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 1529-1537	7.5	28
248	Targeted therapies in metastatic esophageal cancer: advances over the past decade. <i>Critical Reviews in Oncology/Hematology</i> , <b>2014</b> , 91, 186-96	7	28
247	PEGylated $\text{EGd}_2(\text{MoO}_4)_3$ Mesoporous Flowers: Synthesis, Characterization, and Biological Application. <i>Crystal Growth and Design</i> , <b>2013</b> , 13, 4051-4058	3.5	28
246	Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base. <i>Cancer</i> , <b>2017</b> , 123, 3476-3485	6.4	27
245	Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , <b>2014</b> , 13, 219-25	3.8	27
244	Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy. <i>Cancer</i> , <b>2013</b> , 119, 454-62	6.4	27
243	Non-ampullary-duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas. <i>Modern Pathology</i> , <b>2017</b> , 30, 255-266	9.8	26
242	Protein kinase C: a target for therapy in pancreatic cancer. <i>Pancreas</i> , <b>2008</b> , 36, 346-52	2.6	26



241	Combined Effect of Sarcopenia and Systemic Inflammation on Survival in Patients with Advanced Stage Cancer Treated with Immunotherapy. <i>Oncologist</i> , <b>2020</b> , 25, e528-e535	5.7	26
240	Substaging Nodal Status in Ampullary Carcinomas has Significant Prognostic Value: Proposed Revised Staging Based on an Analysis of 313 Well-Characterized Cases. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 4392-401	3.1	25
239	Treatment allocation in patients with early-stage esophageal adenocarcinoma: Prevalence and predictors of lymph node involvement. <i>Cancer</i> , <b>2016</b> , 122, 2150-7	6.4	25
238	CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 600-609	13.4	25
237	HER2 in resected gastric cancer: Is there prognostic value?. <i>Journal of Surgical Oncology</i> , <b>2014</b> , 109, 61-62	2.8	24
236	Breast cancer in women with human immunodeficiency virus infection: implications for diagnosis and therapy. <i>Breast Cancer Research and Treatment</i> , <b>2002</b> , 76, 111-6	4.4	24
235	Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials. <i>Cancer</i> , <b>2020</b> , 126, 575-582	6.4	24
234	Locoregional therapies for metastatic colorectal carcinoma to the liver--an evidence-based review. <i>Journal of Surgical Oncology</i> , <b>2014</b> , 110, 182-96	2.8	23
233	SPARC and DNA methylation: possible diagnostic and therapeutic implications in gastrointestinal cancers. <i>Cancer Letters</i> , <b>2013</b> , 328, 10-7	9.9	23
232	High nuclear hypoxia-inducible factor 1 alpha expression is a predictor of distant recurrence in patients with resected pancreatic adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 91, 631-9	4	23
231	A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2005</b> , 28, 152-6	2.7	23
230	Prolonged survival in pancreatic cancer patients with increased regucalcin gene expression: Overexpression of regucalcin suppresses the proliferation in human pancreatic cancer MIA PaCa-2 cells in vitro. <i>International Journal of Oncology</i> , <b>2016</b> , 48, 1955-64	4.4	23
229	Management patterns and predictors of mortality among US patients with cancer hospitalized for malignant bowel obstruction. <i>Cancer</i> , <b>2015</b> , 121, 1772-8	6.4	22
228	Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?. <i>Oncologist</i> , <b>2015</b> , 20, 981-2	5.7	22
227	Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization. <i>Journal of Vascular and Interventional Radiology</i> , <b>2012</b> , 23, 1286-93.e1	2.4	22
226	A phase I study of flavopiridol and docetaxel. <i>Investigational New Drugs</i> , <b>2006</b> , 24, 305-10	4.3	22
225	Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer. <i>Journal of Cellular Biochemistry</i> , <b>2010</b> , 110, 171-81	4.7	21
224	A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2007</b> , 30, 340-5	2.7	21

223	ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4017-4017	2.2	21
222	A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies. <i>British Journal of Cancer</i> , <b>2013</b> , 108, 762-5	8.7	20
221	Phase I study of bryostatin 1 and gemcitabine. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 7059-62	12.9	20
220	Appendiceal Neuroendocrine, Goblet and Signet-Ring Cell Tumors: A Spectrum of Diseases with Different Patterns of Presentation and Outcome. <i>Cancer Research and Treatment</i> , <b>2016</b> , 48, 596-604	5.2	20
219	Prolonged survival in hepatocarcinoma patients with increased regucalcin gene expression: HepG2 cell proliferation is suppressed by overexpression of regucalcin in vitro. <i>International Journal of Oncology</i> , <b>2016</b> , 49, 1686-94	4.4	20
218	Incidence and prognosis of gastroesophageal cancer in rural, urban, and metropolitan areas of the United States. <i>Cancer</i> , <b>2013</b> , 119, 4020-7	6.4	19
217	High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. <i>Oncologist</i> , <b>2019</b> , 24, 911-920	5.7	19
216	Curcumin analogs: Their roles in pancreatic cancer growth and metastasis. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 10-19	7.5	19
215	Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma. <i>Annals of Surgical Oncology</i> , <b>2011</b> , 18, 3384-90	3.1	18
214	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer. <i>Medical Oncology</i> , <b>2016</b> , 33, 48	3.7	18
213	Cyclooxygenase-2 in gastrointestinal malignancies. <i>Cancer</i> , <b>2019</b> , 125, 1221-1227	6.4	18
212	Pancreatic Cancer and Immunotherapy: Resistance Mechanisms and Proposed Solutions. <i>Journal of Gastrointestinal Cancer</i> , <b>2019</b> , 50, 1-8	1.6	18
211	Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 61, 283-9	3.5	17
210	TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. <i>JMIR Research Protocols</i> , <b>2019</b> , 8, e11545	2	17
209	Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 269-269	2.2	17
208	Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer. <i>Cancer Letters</i> , <b>2017</b> , 402, 110-116	9.9	16
207	Clinicopathologic Features and Outcome of Young Adults With Stage IV Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2015</b> , 38, 543-9	2.7	16
206	Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , <b>2005</b> , 90, 25-31	4.4	16



205	Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery Improves Outcome in Patients With Primary Appendiceal Mucinous Adenocarcinoma: A Pooled Analysis From Three Tertiary Care Centers. <i>Oncologist</i> , <b>2015</b> , 20, 907-14	5.7	15
204	Investigational agents to enhance the efficacy of chemotherapy or radiation in pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2018</b> , 126, 201-207	7	15
203	Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells. <i>Cancer</i> , <b>2017</b> , 123, 4924-4933	6.4	15
202	Oxaliplatin-induced hepatoportal sclerosis, portal hypertension, and variceal bleeding successfully treated with transjugular intrahepatic portosystemic shunt. <i>Clinical Colorectal Cancer</i> , <b>2012</b> , 11, 224-7	3.8	15
201	Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma. <i>Cancer</i> , <b>2013</b> , 119, 3242-50	6.4	15
200	Impact of race, age, and socioeconomic status on participation in pancreatic cancer clinical trials. <i>Pancreas</i> , <b>2010</b> , 39, 967-71	2.6	15
199	Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1167-74	4	14
198	Adjuvant therapy for pancreas cancer in an era of value based cancer care. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 42, 10-7	14.4	14
197	Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. <i>Cancer</i> , <b>2018</b> , 124, 3118-3126	6.4	14
196	Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract. <i>Therapeutic Advances in Medical Oncology</i> , <b>2015</b> , 7, 56-62	5.4	13
195	Morphologic Variants of Pancreatic Neuroendocrine Tumors: Clinicopathologic Analysis and Prognostic Stratification. <i>Endocrine Pathology</i> , <b>2020</b> , 31, 239-253	4.2	13
194	Small molecule tyrosine kinase inhibitors in pancreatic cancer. <i>Biologics: Targets and Therapy</i> , <b>2008</b> , 2, 707-15	4.4	13
193	Clinical Outcomes of Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 257-268	3.8	13
192	PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors. <i>Cancers</i> , <b>2019</b> , 11,	6.6	13
191	Autotaxin determines colitis severity in mice and is secreted by B cells in the colon. <i>FASEB Journal</i> , <b>2019</b> , 33, 3623-3635	0.9	13
190	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs. <i>JCO Oncology Practice</i> , <b>2020</b> , 16, 319-325	2.3	13
189	Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors: Improving Its Prognostic Value for Recurrence of Disease. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 290-298 <sup>3.1</sup>		12
188	Analysis of racial disparities in the treatment and outcomes of colorectal cancer in young adults. <i>Cancer Epidemiology</i> , <b>2019</b> , 63, 101618	2.8	12

187	Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor. <i>Oncology</i> , <b>2017</b> , 93, 336-342	3.6	12
186	Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	12
185	A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4106-4106	2.2	12
184	Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. <i>Oncotarget</i> , <b>2020</b> , 11, 1749-1757	3.3	12
183	Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis. <i>Journal of Gastrointestinal Oncology</i> , <b>2019</b> , 10, 85-94	2.8	12
182	Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. <i>Cancer</i> , <b>2018</b> , 124, 1992-2000	6.4	11
181	Evaluation of Treatment Patterns and Survival Outcomes in Elderly Pancreatic Cancer Patients: A Surveillance, Epidemiology, and End Results-Medicare Analysis. <i>Oncologist</i> , <b>2018</b> , 23, 704-711	5.7	11
180	The flavonoid p-hydroxycinnamic acid exhibits anticancer effects in human pancreatic cancer MIA PaCa-2 cells in vitro: Comparison with gemcitabine. <i>Oncology Reports</i> , <b>2015</b> , 34, 3304-10	3.5	11
179	Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 150-160	6.1	11
178	Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 81, 659-670	3.5	10
177	MicroRNAs as biomarkers and prospective therapeutic targets in colon and pancreatic cancers. <i>Tumor Biology</i> , <b>2016</b> , 37, 97-104	2.9	10
176	Squamous cell cancer of the anal canal in HIV-infected patients receiving highly active antiretroviral therapy: a single institution experience. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2011</b> , 34, 135-9	2.7	10
175	Cytochrome p450 and glutathione transferase expression in squamous cell cancer. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 4412-6	12.9	10
174	Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 593-593	2.2	10
173	Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4110-4110	2.2	10
172	Epigenetics in hepatocellular carcinoma. <i>Seminars in Cancer Biology</i> , <b>2021</b> ,	12.7	10
171	National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. <i>Cancer</i> , <b>2019</b> , 125, 2732-2746	6.4	9
170	Clinical outcomes of rare hepatocellular carcinoma variants compared to pure hepatocellular carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , <b>2019</b> , 6, 119-129	5.3	9

169	Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic metastasis of pancreaticobiliary origin. <i>Journal of Gastrointestinal Oncology</i> , <b>2019</b> , 10, 944-956	2.8	9
168	Treatment utilization and surgical outcome of ampullary and duodenal adenocarcinoma. <i>Journal of Surgical Oncology</i> , <b>2014</b> , 109, 556-60	2.8	9
167	Biomarkers for personalized medicine in GI cancers. <i>Molecular Aspects of Medicine</i> , <b>2015</b> , 45, 14-27	16.7	9
166	Protein kinases C isozymes are differentially expressed in human breast carcinomas. <i>Life Sciences</i> , <b>2009</b> , 84, 766-71	6.8	9
165	Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors. <i>Investigational New Drugs</i> , <b>2005</b> , 23, 57-62	4.3	9
164	Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2021</b> , 44, 74-81	2.7	9
163	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. <i>Investigational New Drugs</i> , <b>2019</b> , 37, 1198-1206	4.3	8
162	Napabucasin (BBI 608), a potent chemoradiosensitizer in rectal cancer. <i>Cancer</i> , <b>2020</b> , 126, 3360-3371	6.4	8
161	Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 682-90	4.3	8
160	Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines. <i>Cancer Medicine</i> , <b>2015</b> , 4, 392-403	4.8	8
159	Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2014</b> , 37, 194-200	2.7	8
158	Tumor angiogenesis therapy using targeted delivery of Paclitaxel to the vasculature of breast cancer metastases. <i>Journal of Drug Delivery</i> , <b>2014</b> , 2014, 865732	2.3	8
157	Clinicopathological analysis of primary epithelial appendiceal neoplasms. <i>Medical Oncology</i> , <b>2010</b> , 27, 1073-8	3.7	8
156	Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial. <i>Journal of Surgical Oncology</i> , <b>2016</b> , 114, 336-41	2.8	8
155	Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. <i>Cancer</i> , <b>2019</b> , 125, 57-67	6.4	8
154	Nonsurgical Management of Rectal Cancer. <i>Journal of Oncology Practice</i> , <b>2019</b> , 15, 123-131	3.1	7
153	Chemotherapy with or Without Definitive Radiation Therapy in Inoperable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , <b>2018</b> , 25, 1026-1033	3.1	7
152	A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2499-2511	3.8	7

151	In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. <i>Journal of Geriatric Oncology</i> , <b>2020</b> , 11, 660-667	3.6	7
150	Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer <b>2020</b> , 8,		7
149	Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers. <i>Oncologist</i> , <b>2020</b> , 25, 414-424.	3.7	6
148	Racial Disparities, Outcomes, and Surgical Utilization among Hispanics with Esophageal Cancer: A Surveillance, Epidemiology, and End Results Program Database Analysis. <i>Oncology</i> , <b>2019</b> , 97, 49-58	3.6	6
147	90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. <i>Journal of Comparative Effectiveness Research</i> , <b>2013</b> , 2, 435-44	2.1	6
146	Abstract 3828: Potent curcumin analogues inhibit pancreatic cancer cell growth and angiogenesis <b>2012</b> ,		6
145	BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4077-4077	2.2	6
144	Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma. <i>Anticancer Research</i> , <b>2012</b> , 32, 3559-63	2.3	6
143	Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy. <i>Cancer</i> , <b>2020</b> , 126, 37-45	6.4	6
142	Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated. <i>Cancer</i> , <b>2020</b> , 126, 4788-4799	6.4	6
141	Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer. <i>Oncologist</i> , <b>2021</b> , 26, 668-675	5.7	6
140	Targeting KRAS in pancreatic cancer: new drugs on the horizon. <i>Cancer and Metastasis Reviews</i> , <b>2021</b> , 40, 819-835	9.6	6
139	Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody. <i>Journal of Drug Targeting</i> , <b>2015</b> , 23, 257-65	5.4	5
138	A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2497-2505	12.9	5
137	An update on the multimodality of localized rectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 108, 23-32	7	5
136	Race-, Age-, and Gender-Based Characteristics and Toxicities of Targeted Therapies on Phase I Trials. <i>Oncology</i> , <b>2018</b> , 95, 138-146	3.6	5
135	Cellular DNA content parameters as prognostic indicators in human astrocytomas. <i>Journal of Neuro-Oncology</i> , <b>2005</b> , 71, 85-9	4.8	5
134	Phase I study of ganetespib (G), capecitabine (C), and radiation (RT) in rectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3596-3596	2.2	5

133	Correlates of financial toxicity in adult cancer patients and their informal caregivers. <i>Supportive Care in Cancer</i> , <b>2022</b> , 30, 217-225	3.9	5
132	FRI-499-Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e619	13.4	4
131	Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma. <i>Expert Opinion on Therapeutic Targets</i> , <b>2012</b> , 16, 707-18	6.4	4
130	Unusual case of antiphospholipid antibody syndrome presenting with extensive cutaneous infarcts in a patient on long-term procainamide therapy. <i>American Journal of Hematology</i> , <b>2003</b> , 72, 154	7.1	4
129	Correlation Patterns Among B7 Family Ligands and Tryptophan Degrading Enzymes in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1632	5.3	4
128	Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2019</b> , 42, 331-336	2.7	4
127	Phase II trial of nivolumab and metformin in patients with treatment refractory microsatellite stable metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 95-95	2.2	4
126	Establishment of human metastatic colorectal cancer model in rabbit liver: A pilot study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0177212	3.7	3
125	Mo1135 Trends in the Incidence of Esophageal Adenocarcinoma and Early Stage Esophageal Adenocarcinoma in the United States. <i>Gastroenterology</i> , <b>2014</b> , 146, S-566-S-567	13.3	3
124	Comprehensive genomic profiling of cancer of the appendix to reveal new routes to targeted therapies.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 608-608	2.2	3
123	Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations. <i>World Journal of Gastroenterology</i> , <b>2020</b> , 26, 4036-4054	5.6	3
122	Clinicopathological features and survival outcomes of rare histologic variants of gallbladder cancer. <i>Journal of Surgical Oncology</i> , <b>2019</b> , 121, 294	2.8	3
121	Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer. <i>Cancer</i> , <b>2020</b> , 126, 4136-4147	6.4	3
120	Induction Therapy in Localized Pancreatic Cancer. <i>Pancreas</i> , <b>2019</b> , 48, 913-919	2.6	3
119	Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results. <i>Journal of Gastrointestinal Cancer</i> , <b>2019</b> , 50, 269-275	1.6	3
118	STAT3 Inhibition for Gastroenteropancreatic Neuroendocrine Tumors: Potential for a New Therapeutic Target?. <i>Journal of Gastrointestinal Surgery</i> , <b>2020</b> , 24, 1138-1148	3.3	3
117	Young Adults With Pancreatic Cancer: National Trends in Treatment and Outcomes. <i>Pancreas</i> , <b>2020</b> , 49, 341-354	2.6	2
116	Comparison of DNA content parameters in paired, fresh tissue pretreatment biopsies and surgical resections from squamous cell carcinoma of the head and neck. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2003</b> , 128, 169-77	5.5	2

115	Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3564-3564	2.2	2
114	HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for novel therapeutic targets.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 235-235	2.2	2
113	Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS526-TPS526	2.2	2
112	Radiotherapy patterns of care in gastric adenocarcinoma: a single institution experience. <i>Journal of Gastrointestinal Oncology</i> , <b>2015</b> , 6, 247-53	2.8	2
111	Long-Term Survival in Stage IV Esophageal Adenocarcinoma with Chemoradiation and Serial Endoscopic Cryoablation. <i>Clinical Endoscopy</i> , <b>2017</b> , 50, 491-494	2.5	2
110	Antiangiogenic activity of the HSP90 inhibitor ganetespib in pancreatic cancer models. <i>FASEB Journal</i> , <b>2013</b> , 27, lb572	0.9	2
109	Anti-angiogenic effects of curcumin and its novel analogs EF-31 and UBS-109 in colorectal cancer. <i>FASEB Journal</i> , <b>2013</b> , 27, lb574	0.9	2
108	Variant anatomy of the biliary system as a cause of pancreatic and peri-ampullary cancers. <i>Hpb</i> , <b>2020</b> , 22, 1675-1685	3.8	2
107	Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review. <i>Clinical Colorectal Cancer</i> , <b>2021</b> , 20, 153-160	3.8	2
106	A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 3337-3348	7.4	2
105	Phase 1 Study of CEP-37250/KHK2804, a Tumor-specific Anti-glycoconjugate Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Targeted Oncology</i> , <b>2016</b> , 11, 807-814	5	2
104	Nonbacterial Thrombotic Endocarditis and Widespread Skin Necrosis in Newly Diagnosed Lung Adenocarcinoma. <i>Case Reports in Oncology</i> , <b>2020</b> , 13, 239-244	1	2
103	Should Signet Ring Cell Histology Alter the Treatment Approach for Clinical Stage I Gastric Cancer?. <i>Annals of Surgical Oncology</i> , <b>2021</b> , 28, 97-105	3.1	2
102	Is adjuvant chemotherapy beneficial for stage II-III goblet cell carcinoid/goblet cell adenocarcinoma of the appendix?. <i>Surgical Oncology</i> , <b>2021</b> , 36, 120-129	2.5	2
101	Survival analysis of colorectal cancer patients treated with first-line modified FOLFOX6 with or without bolus fluorouracil.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 35-35	2.2	2
100	Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. <i>Pancreas</i> , <b>2020</b> , 49, 822-829	2.6	1
99	A patient-centered team approach in oncology. <i>Cancer</i> , <b>2018</b> , 124, 1856-1858	6.4	1
98	Interaction of heat shock protein 90 with hypoxia inducible factor and signal transducer and activator of transcription in colon cancer. <i>Process Biochemistry</i> , <b>2019</b> , 86, 151-158	4.8	1



97	Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer. <i>Case Reports in Oncology</i> , <b>2009</b> , 2, 220-228	1	1
96	Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.. <i>Oncology</i> , <b>2022</b> , 1-9	3.6	1
95	Phase Ib/II trial of siltuximab and spartalizumab in patients in metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS626-TPS626	2.2	1
94	Cost-effectiveness analysis of pharmacokinetic-guided (PK) 5-fluorouracil (5FU) when combined with leucovorin and oxaliplatin (FOLFOX) chemotherapy for metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6527-6527	2.2	1
93	Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 6613-6613	2.2	1
92	Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer (mPC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 368-368	2.2	1
91	Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 658-658	2.2	1
90	Uridine triacetate as a life-saving antidote to capecitabine toxicity.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e21612-e21612	2.2	1
89	Clinical trial experience with uridine triacetate for 5-fluorouracil toxicity.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 655-655	2.2	1
88	Adjuvant treatment for resected sub-centimeter T1 pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4125-4125	2.2	1
87	Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e16207-e16207	2.2	1
86	Epidemiology and treatment of high-grade gastrointestinal neuroendocrine tumors (HG-GI-NETs).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 421-421	2.2	1
85	Impact of genomic alterations (GAs) on outcomes and their distribution by age groups in metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 560-560	2.2	1
84	Immunotherapy in Pancreatic Cancer. <i>Digestive Disease Interventions</i> , <b>2020</b> , 04, 351-357	0.2	1
83	High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 755113	5.3	1
82	Incidence, treatment and survival outcomes of small bowel adenocarcinomas: A National Cancer Database (NCDB) analysis.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e16262-e16262	2.2	1
81	A phase I/II study of trifluridine/tipiracil (TAS-102) in combination with nanoliposomal irinotecan (NAL-IRI) in advanced GI cancers.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS4155-TPS4155	2.2	1
80	Novel Strategies on the Horizon for Metastatic Pancreatic Cancer Management. <i>Oncology &amp; Hematology Review</i> , <b>2019</b> , 15, 27	0.1	1

79	A risk score to predict in-hospital mortality in patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15256-e15256	2.2	1
78	A phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 284-284	2.2	1
77	Racial disparities in treatment and outcomes of colorectal cancer in young adults.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 6559-6559	2.2	1
76	Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 1377-1386	8.7	1
75	Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 1228-1234	8.7	1
74	Impact of Tumor Side on Clinical Outcomes in Stage II and III Colon Cancer With Known Microsatellite Instability Status. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 592351	5.3	1
73	PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 1836-1845	6.1	1
72	Perioperative therapy in metastatic colorectal cancer: Pattern of use and survival outcomes. <i>Journal of Surgical Oncology</i> , <b>2021</b> , 123, 596-605	2.8	1
71	Impact of high-risk features for stage II adenocarcinoma of the appendix. <i>Cancer Treatment and Research Communications</i> , <b>2021</b> , 27, 100329	2	1
70	Frontline therapy for advanced hepatocellular carcinoma: an update.. <i>Therapeutic Advances in Gastroenterology</i> , <b>2022</b> , 15, 17562848221086126	4.7	1
69	A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2007</b> , 30, 101-5	2.7	0
68	Role of Resection of the Primary in Metastatic Well-Differentiated Neuroendocrine Tumors.. <i>Pancreas</i> , <b>2021</b> , 50, 1382-1391	2.6	0
67	Role of resection of the primary in metastatic well/intermediate-differentiated neuroendocrine tumor (NET).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e15693-e15693	2.2	0
66	Phase II randomized, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN G14-198).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 413-413	2.2	0
65	Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 821903	5.3	0
64	Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 728076	5.3	0
63	Successful liver transplantation of recurrent fibrolamellar carcinoma following clinical and pathologic complete response to triple immunochemotherapy: A case report.. <i>Oncology Research and Treatment</i> , <b>2022</b> ,	2.8	0
62	Management and Outcomes of Hospitalized Patients With Primary Neuroendocrine Tumor and Non-Neuroendocrine Tumor Appendiceal Cancers in the United States. <i>World Journal of Oncology</i> , <b>2015</b> , 6, 349-354	16.7	

61	Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3842-3	2.2
60	Peptide Vaccines for Treatment of Colon Cancer: Have We Made Progress?. <i>Current Colorectal Cancer Reports</i> , <b>2014</b> , 10, 477-486	1
59	Tools to optimize the functionality of a leukemia clinical trial team. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 110-6	1.9
58	Breast Cancer in Women with Human Immunodeficiency Virus Infection: Implications for Diagnosis and Therapy. <i>Breast Cancer Research and Treatment</i> , <b>2004</b> , 83, 189-189	4.4
57	Neoadjuvant treatment of pancreatic carcinosarcoma: a case report and review of literature.. <i>Chinese Clinical Oncology</i> , <b>2022</b> ,	2.3
56	A phase I study of pharmacokinetic (PK)-driven sequential dosing of rucaparib (RUB) with irinotecan liposome (nal-IRI) and fluorouracil (5FU) in metastatic gastrointestinal (mGI) and pancreas (PANC) cancers.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 563-563	2.2
55	Characteristics and outcomes of patients with multiple synchronous colon cancer primaries.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 194-194	2.2
54	Impact of local therapy on survival among patients with metastatic anal squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 4-4	2.2
53	Is adjuvant chemotherapy beneficial for stage II-III goblet cell tumors of the appendix?. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 796-796	2.2
52	Resection of pancreatic cancer following induction chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 406-406	2.2
51	STAT3 inhibition for gastroenteropancreatic neuroendocrine tumors: Potential for a new therapeutic target?. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 340-340	2.2
50	Impact of adjuvant chemotherapy in higher risk stage II colon cancer with a deficient mismatch repair (dMMR)/ microsatellite instability-high (MSI-H) profile.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3604-3604	2.2
49	Survival outcomes in gastric and gastroesophageal junction adenocarcinoma treated with peri-operative chemotherapy with or without pre-operative radiotherapy.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 4026-4026	2.2
48	Retrospective study of the safety of administering pegfilgrastim on the same day of 5- Fluorouracil pump disconnect.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e16190-e16190	2.2
47	Early change in blood-based biomarkers and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e15022-e15022	2.2
46	Small Bowel and Appendix Cancers <b>2019</b> , 97-107	
45	Genomic alterations in appendiceal carcinoma using circulating DNA.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 658-658	2.2
44	Phase II randomized, double-blind, study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients hcrn GI14-198.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS475-TPS475	2.2

- 43 Clinical outcomes of hepatocellular carcinoma variants compared to hepatocellular carcinoma.. *Journal of Clinical Oncology*, **2019**, 37, 435-435 2.2
- 42 Blood-based next-generation sequencing analysis of neuroendocrine tumors.. *Journal of Clinical Oncology*, **2019**, 37, 4110-4110 2.2
- 41 Analysis of age, tumor-sidedness, and mismatch repair (MMR) genes with response to immune checkpoint inhibitors (ICIs) in MMR-deficient (dMMR) colorectal cancer (CRC) patients (pts): A multi-institutional study.. *Journal of Clinical Oncology*, **2019**, 37, e15029-e15029 2.2
- 40 Perioperative therapy in patients with metastatic colorectal cancer.. *Journal of Clinical Oncology*, **2019**, 37, e18231-e18231 2.2
- 39 Personalized T cell therapy for metastatic colon cancer.. *Journal of Clinical Oncology*, **2019**, 37, e15183-e15183 2.2
- 38 Mortality from malignant bowel obstruction in hospitalized U.S. cancer patients.. *Journal of Clinical Oncology*, **2014**, 32, 9626-9626 2.2
- 37 Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC).. *Journal of Clinical Oncology*, **2014**, 32, 6502-6502 2.2
- 36 The anatomic location of pancreatic cancer as a prognostic factor for inpatient complications.. *Journal of Clinical Oncology*, **2015**, 33, 247-247 2.2
- 35 Prognostic value of gender in hospitalized pancreatic patients.. *Journal of Clinical Oncology*, **2015**, 33, 256-256 2.2
- 34 Phase Ib study of pasireotide (P), everolimus (E), and selective internal radioembolization therapy (SIRT) for unresectable neuroendocrine hepatic metastases.. *Journal of Clinical Oncology*, **2015**, 33, 4092-4092 2.2
- 33 Management and outcomes of hospitalized patients with primary neuroendocrine tumor (NET) and non-NET appendiceal cancers in the United States.. *Journal of Clinical Oncology*, **2015**, 33, e17722-e17722 2.2
- 32 Pattern of liver-directed therapies and outcomes in cancer patients hospitalized in the United States.. *Journal of Clinical Oncology*, **2015**, 33, e15112-e15112 2.2
- 31 Borderline resectable (BRPC) and locally advanced unresectable (LAPC) pancreas cancer treatment: A single Institution experience.. *Journal of Clinical Oncology*, **2015**, 33, e15260-e15260 2.2
- 30 A molecular biomarker targeted approach to adjuvant therapy for resected pancreatic adenocarcinoma: Results of a phase II prospective trial.. *Journal of Clinical Oncology*, **2016**, 34, 230-230 2.2
- 29 Phase Ib trial of gemcitabine with yttrium-90 in patients with hepatic tumors of pancreatobiliary origin.. *Journal of Clinical Oncology*, **2016**, 34, 460-460 2.2
- 28 Uridine triacetate as a lifesaving antidote for overdoses and severe early-onset 5-fluorouracil and capecitabine toxicities.. *Journal of Clinical Oncology*, **2016**, 34, e21689-e21689 2.2
- 27 Comparative features and overall survival in adenosquamous carcinoma, a rare tumor of the esophagus.. *Journal of Clinical Oncology*, **2016**, 34, e15541-e15541 2.2
- 26 Uridine triacetate for early onset, severe life-threatening toxicities of 5-fluorouracil and capecitabine.. *Journal of Clinical Oncology*, **2016**, 34, e21675-e21675 2.2

- 25 Effect of definitive concurrent therapy with or without surgery on resectable esophageal cancer survival: An analysis of the National Cancer Data Base.. *Journal of Clinical Oncology*, **2016**, 34, 4045-4045<sup>2.2</sup>
- 24 Safety and pharmacokinetics of crizotinib in patients (pts) with hepatic impairment (HI) and advanced cancer.. *Journal of Clinical Oncology*, **2017**, 35, 2552-2552<sup>2.2</sup>
- 23 Treatment, outcomes, and impact of racial disparities on young adults with pancreatic cancer.. *Journal of Clinical Oncology*, **2017**, 35, e18069-e18069<sup>2.2</sup>
- 22 Enrollment into molecular selection trials and impact on patient disposition.. *Journal of Clinical Oncology*, **2017**, 35, e14035-e14035<sup>2.2</sup>
- 21 Safety of trifluridine/tipiracil for metastatic colorectal cancer in African American patients participating in an expanded access program.. *Journal of Clinical Oncology*, **2017**, 35, e15039-e15039<sup>2.2</sup>
- 20 Chemotherapy with or without definitive radiation therapy in locally advanced pancreatic cancer.. *Journal of Clinical Oncology*, **2017**, 35, 4103-4103<sup>2.2</sup>
- 19 Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer (EC).. *Journal of Clinical Oncology*, **2017**, 35, e15607-e15607<sup>2.2</sup>
- 18 Molecularly Targeted Therapies in Pancreatic Cancer **2018**, 219-233
- 17 An analysis of ERCC1, hENT1, RRM1, and RRM2 expression in resected pancreas adenocarcinoma: Implications for adjuvant treatment.. *Journal of Clinical Oncology*, **2012**, 30, 206-206<sup>2.2</sup>
- 16 Novel methods of analyzing long-term trends in incidence and survival applied to gastroesophageal cancers.. *Journal of Clinical Oncology*, **2012**, 30, e14512-e14512<sup>2.2</sup>
- 15 Neuroendocrine tumors (NET) of the gastrointestinal tract: Patterns of management and experience at Winship Cancer Institute of Emory University.. *Journal of Clinical Oncology*, **2013**, 31, 326-326<sup>2.2</sup>
- 14 Early therapy response assessment by apparent diffusion coefficient (ADC) quantification following glass-based yttrium-90 radioembolization for unresectable hepatocellular carcinoma (HCC).. *Journal of Clinical Oncology*, **2013**, 31, e15140-e15140<sup>2.2</sup>
- 13 Survival outcome of ampullary and duodenal adenocarcinomas.. *Journal of Clinical Oncology*, **2013**, 31, e14579-e14579<sup>2.2</sup>
- 12 Multiplatform assessment of anaplastic lymphoma kinase (ALK) gene rearrangement in signet ring cell carcinoma of the gastrointestinal tract.. *Journal of Clinical Oncology*, **2013**, 31, e14612-e14612<sup>2.2</sup>
- 11 Survival trends in chemorefractory unresectable intrahepatic cholangiocarcinoma (ICC) and the effect of yttrium-90 (Y90) radioembolization: SEER versus tertiary cancer center.. *Journal of Clinical Oncology*, **2014**, 32, 342-342<sup>2.2</sup>
- 10 Association of radiation therapy with overall survival in patients undergoing surgery for T3N0M0 adenocarcinoma of the rectum.. *Journal of Clinical Oncology*, **2014**, 32, 528-528<sup>2.2</sup>
- 9 Open-label prospective study of safety and efficacy of glass-based Y-90 radioembolization for infiltrative HCC with PVT.. *Journal of Clinical Oncology*, **2014**, 32, 276-276<sup>2.2</sup>
- 8 Survival trends in unresectable hepatocellular carcinoma and the effect of DEB-TACE: SEER versus tertiary cancer center.. *Journal of Clinical Oncology*, **2014**, 32, 308-308<sup>2.2</sup>

- 7 HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target. *Surgical Oncology*, **2020**, 35, 460-465 2.5
- 6 Survival Outcomes of Acinar Cell Pancreatic Cancer: A National Cancer Database Analysis. *Pancreas*, **2021**, 50, 529-536 2.6
- 5 Clinical features and outcomes of colloid carcinoma of pancreas compared to pancreatic ductal adenocarcinoma.. *Journal of Clinical Oncology*, **2021**, 39, e16259-e16259 2.2
- 4 Treatment outcomes for stage T1b-2 esophagogastric adenocarcinomas.. *Journal of Clinical Oncology*, **2021**, 39, e16085-e16085 2.2
- 3 Survival outcomes of adjuvant chemotherapy in elderly patients with stage III colon cancer.. *Journal of Clinical Oncology*, **2021**, 39, 89-89 2.2
- 2 Impact of primary tumor size/horizontal extent on survival in colorectal cancer.. *Journal of Clinical Oncology*, **2021**, 39, 125-125 2.2
- 1 Impact of socioeconomic status (SES) on colorectal cancer patient survival: An analysis of 890,867 patients in the National Cancer Database (NCDB).. *Journal of Clinical Oncology*, **2021**, 39, 19-19 2.2